Trial Profile
Single- Arm Trial to Identify Potential Markers Underlying Variability in Response to Omalizumab (Xolair) Treatment in Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Atopic dermatitis
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms AMB-WEI-1052-I; AMBITIOUS
- 28 Apr 2014 New source identified and integrated (ClinicalTrials.gov).
- 28 Apr 2014 New trial record